Biotech Values

[oc631]

There's really not a lot of specifics in that, and the other, language though. We've seen no clear guidance from Roche about moving danoprevir forward into Phase 3. I think we really just need to listen to the next Roche CC to get more definitive answers, or at least a strong inkling of what Roche intends to do. I would be surprised if they pushed danoprevir forward with other potentially better HCV PIs out there.

Information from a third party is never as good as directly from the horses (Roche's) mouth but Pharmasset claims Roche told them several months ago they intend to file the NDA for RG7227/RG7128 in 2013. My gut feeling is Roche is pushing on with 7227. If Roche was to license another PI how long would that set the INFORM study back? Being first to market with a DAA, as soon as possible, is of the utmost importance considering a large majority of the warehoused patients in the U.S. will more than likely begin treatment with telaprevir and boceprevir plus SOC early next year. If Roche was done with 7227 they could have used that $175 million towards licensing PSI-7977 or IDX-184, gotten a nuke with QD dosing along with their pick of several PI's in development, and told Intermune to get lost.